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Canonical Wnt signalling requires caveolin-dependent
internalization of low-density lipoprotein receptor-related
protein 6 (LRP6). Here we report that the tumour suppres-
sor and endocytic adaptor disabled-2 (Dab2), previously
described as an inhibitor of Wnt/b-catenin signalling,
selectively recruits LRP6 to the clathrin-dependent endo-
cytic route, thereby sequestering it from caveolin-
mediated endocytosis. Wnt stimulation induces the casein
kinase 2 (CK2)-dependent phosphorylation of LRP6 at
S1579, promoting its binding to Dab2 and internalization
with clathrin. LRP6 receptor mutant (S1579A), deﬁcient in
CK2-mediated phosphorylation and Dab2 binding, fails to
associate with clathrin, and thus escapes the inhibitory
effects of Dab2 on Wnt/b-catenin signalling. Our data
suggest that the S1579 site of LRP6 is a negative regulatory
point during LRP6-mediated dorsoventral patterning in
zebraﬁsh and in allograft mouse tumour models. We
conclude that the tumour suppressor functions of Dab2
involve modulation of canonical Wnt signalling by regu-
lating the endocytic fate of the LRP6 receptor.
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Introduction
Wnt signalling is critical during various developmental and
physiological processes, and is implicated in human disease,
including cancer (Polakis, 2000; Clevers, 2006). Stabilization
and translocation of intracellular b-catenin into the nucleus
are essential in canonical Wnt signalling. In the absence of
Wnt, b-catenin is assembled in a multimeric b-catenin
destruction complex that contains Axin, adenomatous
polyposis coli (APC), casein kinase I (CKI) and glycogen
synthase kinase 3 (GSK3). In this complex, b-catenin is
sequentially phosphorylated by CKI and GSK3 and targeted
for degradation through the SCF
b-TrCP-mediated ubiquitin-
proteasome pathway. In the presence of Wnt, activation of
the Frizzled (Fz) and low-density-lipoprotein receptor-related
protein co-receptors (LRP5/6/arrow) leads to destabilization
of the b-catenin destruction complex, inactivation of GSK3
and inhibition of b-catenin phosphorylation and degradation
(Fuerer et al, 2008). Stabilized b-catenin then enters the
nucleus and interacts with transcriptional regulators,
including leukocyte enhancer factor-1 and T cell factor, and
leads to Wnt responsive gene expression (MacDonald et al, 2009).
Mechanistic details of how Wnt stimulation leads to
b-catenin stabilization and GSK3 inactivation are emerging,
and it appears that receptor phosphorylation and internaliza-
tion play critical roles. Wnt induces clustering of Fz and
lipoprotein receptor-related protein 6 (LRP6) receptors on
aggregates of the scaffolding protein Dvl to form endocytic
‘LRP6 signalosomes’ (Bilic et al, 2007), leading to the
sequential phosphorylation of LRP6 co-receptor by a ‘dual
kinase’ mechanism involving GSK3 and CK1 at multiple
PPPSP sites. This phosphorylation of LRP6 promotes the
recruitment and engagement of LRP6 with Axin and the
b-catenin destruction complex (Davidson et al, 2005; Zeng
et al, 2005), ultimately leading to GSK3 inactivation and accu-
mulation of b-catenin. Wnt also stimulates the formation of
phosphatidylinositol 4, 5-bisphosphate, through Fz and Dvl,
to promote LRP6 aggregation and phosphorylation, as well as
Axin translocation (Pan et al, 2008). In addition, these
phospho-LRP6 signalosomes contain caveolin (Yamamoto
et al, 2006), a marker of caveolae (cholesterol-rich
invaginations of the plasma membrane), which colocalizes
with LRP6 and is required for Wnt-mediated LRP6
endocytosis and b-catenin accumulation. Subsequent
studies (Yamamoto et al, 2008) have shown that LRP6
internalization can occur through both caveolin- and
clathrin-dependent pathways in order to activate and inhibit
b-catenin signalling, respectively. Wnt3A stimulation induces
caveolin-dependent internalization of LRP6, as well as its
phosphorylation and recruitment of Axin to the plasma
membrane, ultimately leading to b-catenin accumulation. In
contrast, Dickkopf 1 (DKK1), which inhibits Wnt3A-
dependent stabilization of b-catenin, induced the
internalization of LRP6 with clathrin and failed to induce
LRP6 phosphorylation and b-catenin stabilization (Yamamoto
et al, 2008). In addition, noncanonical Wnt5a signalling
requires Fz2-induced internalization through clathrin to
activate Rac and inhibit b-catenin accumulation (Sato et al,
2010). More recent studies not only support the role of
endocytosis in Wnt-mediated signalling but also
mechanistically link receptor internalization to inhibition of
GSK3. Wnt signalling is shown to trigger the sequestration of
GSK3 from the cytosol into multivesicular bodies (MVBs) so
that the enzyme becomes separated from its cytosolic
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signalosomes are internalized, presumably in caveolin-
containing vesicles, and recruited to the ESCRT (endosomal
sorting complex required for transport) complex and sorted
to vesicles destined for formation of MVBs, wherein GSK3 is
sequestered from cytosolic b-catenin, which accumulates,
enters the nucleus and engages in transcriptional activation
(Taelman et al, 2010).
Disabled-2 (Dab2) is a widely expressed endocytic adaptor
protein shown to be involved in several receptor-mediated
signalling pathways (Xu et al, 1995; Hocevar et al,2 0 0 1 ;
Prunier et al, 2004). Its expression levels have a signiﬁcant
impact on cancer development and cellular differentiation
(Morris et al, 2002; Jiang et al, 2008). Aberrantly low levels of
Dab2 protein have been found in many tumour-derived cell
lines (Sheng et al, 2000) and its ectopic expression in these
cancer cell lines results in cell cycle arrest and a decreased
rate of cell proliferation (Zhoul et al, 2005). As such, Dab2
has been assigned the label of a tumour suppressor gene
(Tong et al, 2010). In addition, Dab2 plays a critical role in
cellular differentiation and lineage commitment. Its
expression is upregulated and essential during mega-
karyocytic differentiation (Tseng et al, 2001) and during
retinoic acid (RA)-induced differentiation of F9
teratocarcinoma cells into visceral endoderm-like cells
(Smith et al, 2001).
In the current study we conﬁrm the concept of ‘two
endocytic routes-two outcomes’ proposed for Wnt signalling
(Yamamoto et al, 2008) and demonstrate that Dab2
expression levels regulate whether LRP6 is internalized
through the caveolin or clathrin endocytic pathways. We
show that LRP6 binds directly to Dab2 in a Wnt- and casein
kinase 2 (CK2)-dependent manner. Dab2 has no effect on the
rate of LRP6 internalization but rather regulates its
interaction with caveolin or clathrin. In the absence of
Dab2 LRP6 interacts with caveolin in a Wnt-dependent
manner, and in its presence Wnt stimulation leads to
sequestration of LRP6 with clathrin. Collectively, the data
suggest that the tumour suppressor functions of Dab2 involve
modulation of Wnt/b-catenin signalling by regulating the
endocytic fate of the LRP6 receptor.
Results
Caveolin-mediated endocytosis is essential for
Wnt/b-catenin signalling
To evaluate the role of endocytosis in Wnt/b-catenin signal-
ling, we employed a dominant-negative dynamin (DN) K44A
that acts as an inhibitor of both clathrin and caveolin-
dependent receptor endocytosis (Doherty and McMahon,
2009). Co-transfection of mouse F9 cells with the Wnt/
b-catenin TOPFlash reporter and increasing concentrations
of DN K44A results in dose-dependent inhibition of Wnt3A-
mediated transactivation (Figure 1A). To characterize the
endocytic pathway mediating Wnt3A-induced TOPFlash
transactivation, we treated cells with monodansyl-cadaverine
(MDC), known to block clathrin-mediated endocytosis, or
nystatin, which disrupts lipid rafts and inhibits caveolin-
dependent endocytosis (Yamamoto et al, 2008), prior to
stimulation with Wnt3A. The results (Figure 1B) demonstrate
that in F9 cells nystatin, and not MDC, inhibits Wnt3A-
induced TOPFlash transactivation. In addition, in F9 cells
ectopically expressing Dab2 (F9-Dab2 cells), TOPFlash trans-
activation was signiﬁcantly abolished regardless of nystatin
or MDC treatment (Figure 1B). Further, F9 cells are demon-
strated to be Wnt signalling competent as shown by nuclear
b-catenin accumulation and cyclin D1 induction
(Figure 1C), whereas in F9 cells ectopically expressing
Dab2 (F9-Dab2 cells) Wnt/b-catenin signalling is attenuated
(Figure 1C). Conﬁrming the TOPFlash transactivation
shown above, nystatin, and not MDC, treatment of F9
cells blocks Wnt3A-induced nuclear b-catenin accumulation
and cyclin D1 expression (Figure 1D), but in F9-Dab2 cells
Dab2 inhibits these Wnt3A-induced responses irrespective
of whether the caveolin (nystatin) or clathrin (MDC)
endocytic pathway is modulated (Figure 1E). To test this
further, we silenced both caveolin and clathrin in F9 and
F9-Dab2 cells by siRNA. The results demonstrate that
caveolin knockdown blocks Wnt/b-catenin signalling in
F9 cells, whereas clathrin knockdown attenuates the inhi-
bitory effect of Dab2 on Wnt/b-catenin signalling in F9-
Dab2 cells (Supplementary Figure S1). These results suggest
that Dab2 sequesters LRP6 towards clathrin, away from its
interaction with caveolin, and that its inhibitory effect does
not require LRP6 endocytosis.
Dab2 has no effect on the internalization rate of LRP6
To address the effects of Dab2 on LRP6 endocytosis more
directly, we labelled cell surface proteins with a reversible
biotinylating agent, Sulfo-NHS-SS-Biotin, prior to Wnt3A
treatment for various lengths of time to allow internalization
of cell surface proteins including LRP6. After treatment,
biotin was cleaved (reduced) or not (non-reduced) from all
remaining cell surface proteins using glutathione (Seme ¨nov
et al, 2008). Internalized cell surface proteins, including
LRP6, are protected from the biotin removal procedure. We
observed that total biotin-labelled LRP6 was not affected by
either Wnt3A treatment or Dab2 expression (Figure 1F; ‘non-
reduced’ lanes). We also observed a time-dependent inter-
nalization of LRP6 following Wnt3A treatment, which was
not effected by the expression of Dab2. In both F9 and
F9-Dab2 cells, LRP6 is rapidly internalized following Wnt3A
treatment, with maximal internalization observed at 1–2h,
followed by its reappearance on the cell surface at 4h
(Figure 1F; ‘reduced’ lanes). a-EGFR receptor immunoblot-
ting was used as a control, demonstrating its lack of inter-
nalization in response to Wnt3A stimulation. The results also
demonstrate that nystatin, and not MDC, blocks LRP6 inter-
nalization in F9 cells, whereas in F9-Dab2 cells MDC, and not
nystatin, blocks LRP6 internalization (Supplementary Figure
S2). Thus, Dab2 does not affect LRP6 internalization but
rather sequesters the receptor towards an interaction with
clathrin and not caveolin.
Alternatively, we also compared the amount of cell surface
LRP6 available for biotin labelling following Wnt3A-induced
internalization. The results (Figure 1G) demonstrate that in
the absence (F9 cells) or presence of Dab2 (F9-Dab2 cells)
LRP6 is rapidly internalized in response to Wnt3A (maxi-
mally between 1–2h) and recycled to the cell surface for
labelling at 4h. These Wnt3A-induced rates of LRP6 inter-
nalization are consistent with those presented above and,
importantly, demonstrate that Dab2 expression does not
affect the internalization rate of LRP6.
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clathrin-dependent endocytosis
Since Dab2 had no effect on the endocytic rate of LRP6,
we next examined, by co-immunoprecipitation analyses,
whether it might regulate LRP6’s internalization route. The
results (Figures 2A and B) demonstrate that in the absence of
Dab2 (F9 cells) LRP6 co-immunoprecipitates caveolin in a
Wnt-dependent manner, whereas in the presence of Dab2
(F9-Dab2 cells) LRP6 co-immunoprecipitates clathrin also in
a Wnt-dependent manner. Similar results were observed in
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Figure 1 Caveolin-mediated endocytosis is essential for Wnt/b-catenin signalling and Dab2 has no effect on the internalization rate of LRP6.
(A) Increasing concentrations of DN K44A were co-transfected into F9 cells with 0.5mg of TOP/FOPFlash luciferase reporter construct and
luciferase activity assays were performed and quantitated. (B) F9 and F9-Dab2 cells were transfected with 0.5mg of TOP/FOPFlash luciferase
reporter constructs. Cells were pre-treated for 1h with the indicated concentration of nystatin or MDC prior to Wnt3A stimulation and
luciferase activity determination. (C) F9 and F9-Dab2 cells were treated with Wnt3A conditioned media for the indicated times, and whole-cell
lysates (WCL) were immunoblotted with a–b-catenin, a-cyclin D1 and a-Dab2 antibodies. a-Hsp90 immunoblot is used as a loading control.
(D) F9 and (E) F9-Dab2 cells were pre-treated with nystatin (100mg/ml) or MDC (50mM) for 1h prior to Wnt3A stimulation for the indicated
times. WCL were immunoblotted with a–b-catenin and a-cyclin D1 antibodies. (F) F9 and F9-Dab2 cell surface proteins were biotinylated using
a reversible biotinylation agent (cleavable Sulfo-NHS-SS-Biotin). Following labelling, cells were stimulated with Wnt3A for the indicated times
at 371C and cells were split into two groups. WCL from one group (non-reduced) were precipitated with avidin-agarose beads followed by
immunoblot analysis with a-LRP6 antibody. The other group of cells (reduced) was treated with a glutathione-containing solution to strip away
any biotinylated proteins remaining on the cell surface. WCL were prepared and internalized cell surface proteins protected from biotin
stripping were precipitated with avidin-agarose beads followed by immunoblotting with a-LRP6 antibody. EGF receptor endocytosis was used
as control (immunoblotting with a-EGF receptor antibody). (G) F9 and F9-Dab2 cells were stimulated with Wnt3A for the times indicated and
placed at 41C for a 1h labelling with a biotinylation agent (non-cleavable Sulfo-NHS-LC-Biotin). WCL were prepared and biotin-labelled cell
surface proteins were precipitated with avidin-agarose beads and analysed by immunoblotting with a-LRP6 antibody. Figure source data can be
found with the Supplementary data.
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S3). To further examine this redistribution of LRP6 towards
clathrin by Dab2, we fractionated the lipid raft (caveolin-
containing) and nonlipid raft (clathrin-containing) fractions
by sucrose density gradient centrifugation. The detergent-
resistant membranes including caveolin-1 (Figure 2C, frac-
tions 3, 4 and 5) were present in the lighter-density fractions,
whereas the soluble membranous and non-membranous
materials including clathrin (fractions 7–10) were present in
the higher-density fractions. As depicted in Figure 2C, Wnt3A
stimulation had little effect on the relative distribution of
either caveolin or clathrin, either in the absence (F9 cells) or
in the presence of Dab2 (F9-Dab2 cells). LRP6 and phospho-
LRP6 (S1490) distributions, on the other hand, were signiﬁ-
cantly impacted by the presence of Dab2. In the absence of
Dab2, in F9 cells, LRP6 is shown to co-sediment with the
lighter caveolin-containing fractions and Wnt3A stimulation
appears to promote this distribution. In the presence of Dab2,
in F9-Dab2 cells, LRP6 similarly co-sediments with the
caveolin-containing fractions; however, following Wnt3A
stimulation, LRP6 redistributes with the higher-density
clathrin-containing fractions (Figure 2C). Furthermore, phos-
pho-LRP6 (S1490, indicative of activated Wnt signalling),
which co-sediments with caveolin-containing fractions in
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Figure 2 Dab2 shunts LRP6 towards clathrin-dependent endocytosis. (A) Flag-tagged LRP6 (10mg) was transfected into F9 and F9-Dab2 cells.
Following transfection, cells were treated with Wnt3A for the times indicated and WCL were immunoprecipitated with control a-IgG or a-Flag
antibody. Immunocomplexes were subjected to immunoblot analysis with a-caveolin, a-clathrin and a-Flag antibodies. WCL were also
immunoblotted with a-Dab2 antibody to demonstrate relative Dab2 levels. (B) Flag-tagged LRP6 (10mg) was transfected into F9 Dab2 cells and,
following transfection, stimulated with Wnt3A for the indicated times. WCL were subjected to immunoprecipitation with a-clathrin, a-caveolin
and a-Flag antibodies. Immunocomplexes were immunoblotted with a-Dab2 antibody to detect clathrin/Dab2, caveolin/Dab2 and Flag-LRP6/
Dab2 interactions. WCL were also immunoblotted with a-Dab2 antibody for demonstrating relative Dab2 levels. IgG antisera was used as
negative control for the various immunoprecipitations. (C) WCL from F9 and F9-Dab2 cells treated with or without Wnt3A for 1h were
fractionated by sucrose density gradient centrifugation. Fractions were collected and aliquots of each were analysed by immunoblotting with
a-caveolin, a-clathrin, a-LRP6 and a-p-LRP6 (S1490). (D) Pooled sucrose gradient fractions (light fractions no. 3–5 and heavy fractions
no. 8–10) were immunoprecipitated with a-caveolin (left panels) and a-clathrin (right panels) antibodies. Immunocomplexes were
immunoblotted with a-LRP6, a-Axin, a-GSK3b, a-Dab2, and a-caveolin or a-clathrin. IgG antisera was used as negative control for the
various immunoprecipitations. Figure source data can be found with the Supplementary data.
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following Wnt3A stimulation. To further probe the activation
of Wnt/b-catenin signalling in the various gradient fractions,
we pooled the lower (fractions 3–5) and higher (fractions
8–10) density fractions and determined the relative associa-
tions and distributions of other b-catenin modulators
(Figure 2D). As shown in the ﬁgure, in F9 cells, a-caveolin
Ips co-immunoprecipitate LRP6, Axin and GSK3b in a Wnt-
dependent manner, whereas in F9-Dab2 cells, a-clathrin Ips
co-immunoprecipitate only LRP6 in a Wnt3A-dependent
manner, and not Axin or GSK3b. Collectively, these results
suggest that Dab2 regulates the localization of the LRP6
receptor following Wnt3A stimulation. In the presence
of Dab2, Wnt3A promotes LRP6 association with clathrin,
resulting in its failure to interact with and be phosphorylated
by the b-catenin destruction complex.
To directly observe the effects of Dab2 on the endocytic fate
of the LRP6 receptor, we carried out immunoﬂuorescence
analyses of LRP6 colocalization with caveolin or clathrin in
the absence (F9 cells) or presence (F9-Dab2 cells) of Dab2.
The results show that LRP6 is primarily localized peripherally
along the cell surface and that caveolin is also membrane
associated, as well as found in other regions of the cell.
Wnt stimulation, in the absence of Dab2, promotes interna-
lization of LRP6 and its co-localization with caveolin
(Figure 3A). Quantitatively, B41% of the LRP6 puncta were
co-localized with caveolin and not clathrin (Supplementary
Figure S4A). In the presence of Dab2, although LRP6 is
DAPI Caveolin LRP6 Merge
DAPI Clathrin LRP6 Merge
A
B
F9
F9-
Dab2
–Wnt
+Wnt
–Wnt
+Wnt
F9
F9-
Dab2
–Wnt
+Wnt
–Wnt
+Wnt
Figure 3 Subcellular distribution and co-localization of LRP6/caveolin and LRP6/clathrin in the absence and presence of Dab2.
Immunoﬂuorescence of caveolin and LRP6 (A) and clathrin and LRP6 (B) in F9 and F9-Dab2 cells treated with or without Wnt3A for 1h.
After treatment all cells were ﬁxed and stained with a-LRP6, a-caveolin or a-clathrin antibodies. LRP6 is shown in green, and caveolin and
clathrin are shown in red. Co-localization of LRP6 with caveolin or clathrin is depicted by the yellow in the panels labelled ‘merge’. DAPI was
used to stain the nuclei. Scale bars, 5mm.
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co-localize with caveolin (Figure 3A). Clathrin staining in F9
cells is primarily restricted to the cell surface (Figure 3B), and
following Wnt3A stimulation it fails to co-localize with the
LRP6 receptor. In contrast, in F9-Dab2 cells, Wnt3A treatment
promotes LRP6/clathrin co-localization in cytoplasmic punc-
ta (Figure 3B). Quantitatively, B44% of the LRP6 puncta
co-localize with clathrin and not caveolin (Supplementary
Figure S4B). Meanwhile, in F9 cells B57% of internalized
LRP6 co-localizes with Axin and B39% with GSK3b, con-
ﬁrming Dab2’s inhibitory effect on Wnt/b-catenin signalling
(Supplementary Figure S5). These immunocytochemical ana-
lyses conﬁrm the biochemical assays and demonstrate that
Dab2 regulates the internalization of LRP6 and dictates
whether it is endocytosed through the caveolin or clathrin
pathways.
Dab2 interactions with LRP6
To further characterize Dab2/LRP6 interactions, we per-
formed co-immunoprecipitation analyses in F9-Dab2 cells
with LRP6 membrane-tethered intracellular domain con-
structs (Figure 4A). The results demonstrate that the full-
length intracellular domain of LRP6 (DN) containing the
5 PPP(S/T)P motifs is capable of immunoprecipitating Dab2
(Figure 4A). The DNG construct that contains the C-terminal
3 PPP(S/T)P motifs is also capable of interacting with Dab2.
Deletion and/or mutation of the N-terminal 2 PPP(S/T)P
motifs has no effect on Dab2 interaction. But for interaction
with Dab2, the C-terminal domain-containing 3 PPP(S/T)P
motifs are required (Figure 4A). Importantly, the data also
demonstrate that overexpression of these constructs, without
Wnt3A stimulation, is sufﬁcient to induce interaction with
Dab2, supporting previous studies demonstrating that mere
overexpression of these motifs activates Wnt/b-catenin sig-
nalling (Tamai et al, 2004). Reciprocally, the N-terminal 247
amino acids of Dab2, including the phosphotyrosine-binding
domain (PTB), are required for interacting with endogenous
LRP6 (Figure 4B), and this interaction requires Wnt stimula-
tion, in that in the absence of Wnt3A treatment full-length
Dab2 could not co-immunoprecipitate LRP6 (Figure 4B; FL-).
Direct interaction of Dab2 with LRP6 is shown in Figure 4C,
demonstrating that a GST fusion of the PTB domain of Dab2
(GST-PTB) is capable of precipitating overexpressed intracel-
lular LRP6 (DN) and the C-terminal 3 PPP(S/T)P (DNG) LRP6
constructs ectopically expressed in cells. The C-terminal
phosphorylation motifs are required in that the DN1 con-
struct, lacking these, fails to bind the Dab2 PTB domain.
Thus, the PTB domain of Dab2 is required for binding directly
to the intracellular domain of LRP6.
Wnt-induced phosphorylation of LRP6 by GSK3 promotes
the engagement of LRP6 with the scaffolding protein Axin
(Zeng et al, 2005). To determine whether phosphorylation of
LRP6 is required for Dab2 interactions, we performed in situ
mutagenesis of all possible phosphorylation sites within the
DNG construct region of Flag-tagged full-length LRP6. We
mutated Ser, Thr and Tyr residues to Ala (Figure 4D and
Supplementary Figure S6A) in the context of the full-length
Flag-tagged LRP6 construct and one of the mutant constructs
containing Ala substitutions in all three of the C-terminal
PPP(S/T)P motifs (nos. 1572, 1590 and 1607). The data
demonstrate that of all the possible phosphorylation sites
within this region, the only mutant that completely inhibited
Wnt3A-induced Dab2/LRP6 interaction was the phospho-
mutant at Ser1579 (Figure 4D). When transfected in
F9-Dab2 cells with the TOP/FOPFlash reporter, this mutant
(S1579A) also failed to attenuate Wnt-induced transactiva-
tion of this promoter as efﬁciently as the other phospho-
mutant LRP6 constructs (Supplementary Figure S6B).
Analysis of this site (SAEE) suggests that it is conserved in
LRP5/6 and Arrow, and that it conforms to the CK2 phos-
phorylation consensus SxEE/D (Pinna, 2002).
Further support for CK2-mediated phosphorylation of LRP6
at S1579 is provided by the in vitro kinase assay using in vitro
transcribed and translated recombinant WT (wild type)-DNG
LRP6 or phospho-mutant S1579A DNG LRP6 as substrate and
either puriﬁed recombinant CK2 kinase or a-CK2 immuno-
precipitates as the source of kinase. As shown in Supple-
mentary Figure S7A (upper panel), when [
35S]-methionine-
labelled substrate is employed, puriﬁed CK2 and Ips from
Wnt3A-stimulated cells promote the upward mobility shift of
the WT-DNG LRP6 and not the phospho-mutant S1579A DNG
LRP6. In the absence of puriﬁed CK2 or with a-CK2 Ips from
control, non-stimulated cells, neither the band corresponding
to WT-DNG LRP6 nor the phospho-mutant S1579A DNG LRP6
is upwardly shifted. When the in vitro assay is performed
with [
32P]-g-ATP, again only the WT-DNG LRP6 and not the
phospho-mutant S1579A DNG LRP6 is directly phosphory-
lated by either puriﬁed CK2 or a-CK2 Ips from Wnt3A-
stimulated cells (Supplementary Figure S7A, lower panel).
Further, employing an in vitro kinase assay with speciﬁc CK2
peptide substrate, the data (Supplementary Figure S7B) de-
monstrate that Wnt3A stimulation of either F9 or F9-Dab2
cells results in a time-dependent induction of CK2 activity.
To test whether CK2-mediated phosphorylation of this site
modulated LRP6/Dab2 interactions, we transfected F9-Dab2
cells with Flag-tagged WT or S1579A phospho-mutant LRP6
constructs and treated the cells with apigenin, a selective
inhibitor of CK2, prior to stimulation with Wnt3A
(Figure 4E). WT-LRP6, and not the phospho-mutant S1579A
construct, is shown to co-immunoprecipitate Dab2 and cla-
thrin following Wnt3A stimulation (Figure 4E). Co-immuno-
precipitation of LRP6 with Dab2 and clathrin does not occur
in the absence of Wnt3A stimulation. The phospho-mutant
S1579A construct is still capable of co-immunoprecipitating
caveolin in Wnt3A-stimulated cells, suggesting that the S1579
site is speciﬁc for LRP6 association with Dab2 and clathrin
and not caveolin. Further, apigenin inhibits, in a dose-depen-
dent manner, Wnt3A-induced interaction of WT-LRP6 with
Dab2 and clathrin. These data are supported by the TOP/
FOPFlash luciferase data (Supplementary Figure S8) demon-
strating that, in F9-Dab2 cells, Dab2 inhibits reporter trans-
activation induced by the WT-LRP6 receptor but not by the
S1579A phospho-mutant LRP6 receptor. Further, Dab2 inhi-
bition of WT-LRP6-mediated reporter transactivation is sen-
sitive to apigenin whereas the S1579A phospho-mutant LRP6
is not. In addition, sucrose sedimentation analysis (Supple-
mentary Figure S9) demonstrates that in the presence of Dab2
(F9-Dab2), the phosphomutant S1579A LRP6 receptor fails to
shift towards the heavier clathrin fractions upon Wnt3A
stimulation as does the WT-LRP6 (compare with Figure 2C).
The distribution of the S1579A LRP6 receptor is similar
±Wnt3A stimulation in the absence (F9 cells) or presence
(F9-Dab2) of Dab2. This indicates that the mutant can inter-
act with caveolin and shift distribution towards the lighter
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Figure 4 Dab2 interacts with LRP6. (A) Schematic of the VSVG-tagged LRP6 intracellular constructs utilized. The ﬁve reiterated PPPS/TP
motifs are designated as a, b, c, d and e, and the asterisks (*) indicate an S or T to A substitution. ‘TM’ indicates the position of the
transmembrane region of LRP6. Lower panels: all constructs were transfected into F9-Dab2 cells and WCL were prepared and subjected to
immunoprecipitation with either a-VSVG antibody or a-IgG antisera (as negative control). Immunocomplexes were analysed by immunoblot-
ting with a-Dab2 antibody to detect LRP6/Dab2 interactions and with a-VSVG to detect the expression of the various constructs. (B) Schematic
of various Flag-tagged Dab2 constructs utilized. Lower panels: Dab2 constructs were transfected into F9 cells and, following transfection,
treated with Wnt3A for 2h. WCL were subjected to immunoprecipitation analysis with a-Flag antibody and a-IgG antisera (as negative control).
Immunocomplexes were analysed by immunoblotting with a-LRP6 to detect Dab2/LRP6 interactions and with a-Flag to detect the expression of
the various Dab2 constructs. (C) VSVG-tagged LRP6 intracellular mutant constructs DN, DN1 and DNG were transfected into F9 cells and
treated with Wnt3A for the times indicated. WCL were subjected to GST-PTB pulldown assays (GST fusion protein with the N-terminal PTB
domain of Dab2). The precipitated complexes were analysed by immunoblotting with a-VSVG to detect PTB/LRP6 interactions. (D) Schematic
of the intracellular domain of LRP6 and of the various phospho-mutant sites generated. These phospho-mutants were generated in the context
of full-length LRP6 and cloned in Flag-pCS2 expression vector. Also depicted is the consensus CK2 phosphorylation site ‘SAEE’ in LRP6.
Constructs were transfected into F9 Dab2 cells and following transfection treated with Wnt3A for 2h. WCL were immnunoprecipitated with
a-Flag antibody and a-IgG antisera (as negative control). Immunocomplexes were analysed by immunoblotting with a-Dab2 to detect Dab2/
LRP6 interactions and with a-Flag to detect the expression of the various Dab2 constructs. (E) Flag-tagged WTand phospho-mutant S1579A
LRP6 constructs were transfected into F9 Dab2 cells. Following transfection, cells were pre-treated with apigenin (10 and 20mM) for 30min
prior to a 2h Wnt3A stimulation. WCL were immunoprecipitated with a-Flag antibody followed by immunoblotting with a-Dab2, a-clathrin
and a-caveolin. (F) siDab2 F9 cells, WT F9 cells, control shRNA F9 cells and CK2 shRNA F9 cells were treated with 100nM RA for 3 days.
Following treatment, cells were stimulated±Wnt3A for 2h and WCL were immunoprecipitated with a-clathrin. The precipitated complexes
were analysed by immunoblotting with a-Dab2 and a-LRP6 to detect clathrin/LRP6 and clathrin/Dab2 interactions. (G) Relative protein
expression in the cells in (F) was detected by immunoblotting with a-LRP6, a-Dab2, a-clathrin and a-CK2 antibodies. Figure source data can be
found with the Supplementary data.
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interact with clathrin and fails to redistribute with the heavier
clathrin fractions upon Wnt3A stimulation. These data sug-
gest that Wnt3A-mediated phosphorylation of S1579 of LRP6
by CK2 is required for its association with Dab2 and clathrin.
To determine whether endogenous Dab2 can mediate LRP6/
clathrin interactions, we treated F9 and siDab2-F9 cells with
RA for 3 days to induce endogenous Dab2 expression (Jiang
et al, 2008). In siDab2 F9 cells, without Dab2, there is no
clathrin/LRP6 interaction even in the presence of Wnt3A,
while RA-induced endogenous Dab2 in parental F9 cells
mediates clathrin/LRP6 interactions in the presence of
Wnt3A and this interaction is abrogated by CK2 knockdown
(Figure 4F). The relative LRP6, Dab2, clathrin and CK2
expression levels in siDab2 F9 cell and F9 cells are shown in
Figure 4G). Conﬁrming that endogenous Dab2 inhibits Wnt/b-
catenin signalling, Wnt3A-induced phospho-LRP6, Axin2 and
b-catenin accumulation are shown to be attenuated in
RA-treated F9 cells but not in RA-treated siDab2 F9
cells (Supplementary Figure S10). These data conﬁrm that
endogenous Dab2 can mediate clathrin/LRP6 interactions
in the presence of Wnt and that these interactions are CK2-
dependent.
LRP6 S1579A mutant neutralizes Dab2 inhibition of
Wnt3A-mediated dorsoventral patterning in zebraﬁsh
Previous studies have shown that ectopic expression of Dab2
phenocopies Axin overexpression, resulting in inhibition of
Wnt/b-catenin signalling and altered dorsoventral patterning
(Rui et al, 2007; Jiang et al, 2009). To determine whether
modulation of LRP6/Dab2 interactions, through the S1579
site of LRP6, mediates any effects on Wnt-mediated
dorsoventral patterning, we suppressed endogenous
zebraﬁsh LRP6 expression, by antisense morpholinos, and
rescued LRP6 expression using human WTor S1579A mutant
LRP6, not targeted by the zebraﬁsh-speciﬁc LRP6 anti-sense
morpholinos, in the absence or presence of Dab2. Injection of
antisense morpholinos speciﬁc for zebraﬁsh LRP6 (MO
zLRP6), and not control morpholinos (control MO), into
fertilized one-cell-stage embryos resulted in two different
populations of abnormal embryos 24h post fertilization
(Figure 5A). The ventralized phenotype is caused by injection
and accumulation of nucleotides in the future dorsal side,
whereas the dorsalized phenotype results from microinjec-
tion and nucleotide accumulation in the future ventral side
(Rui et al, 2007). Altered phenotypes of the zLRP6
knockdown (MO zLRP6) can be rescued by co-injection
with either the human WT LRP6 (WT hLRP6) or the
S1579A mutant LRP6 (hLRP6 S1579A), demonstrating
that human LRP6 can complement zLRP6 in mediating
dorsoventral patterning (Figure 5A). Rescue of the zLRP6
knockdown altered phenotype by WT hLRP6 is not observed
if microinjection is performed in the presence of Dab2 mRNA
(MO zLRP6þWT hLRP6þDab2). Injection of Dab2 mRNA
inhibits the ability of the WT hLRP6 receptor to rescue the
zLRP6 knockdown phenotype. In contrast, co-microinjection
of Dab2 mRNA with the S1579A LRP6 mutant has no
inhibitory effect on the ability of the hLRP6 S1579A receptor
to rescue the zLRP6 knockdown phenotype (MO zLRP6þ
hLRP6 1579AþDab2). These representative morphological
views are expanded and conﬁrmed by the data shown in
Figure 5B, where dose-dependent effects of the various
morpholinos and microinjected mRNAs are shown demon-
strating that human WTand S1579A mutant LRP6 expression
can rescue the zLRP6 knockdown, and that only the human
WT LRP6 receptor, and not the S1579A mutant, is suscep-
tible to attenuation by Dab2. Appropriate expression of the
injected hLRP6 receptors and Dab2 mRNAs in oocyte ex-
tracts is shown in Figure 5C, and the levels of WT hLRP6,
hLRP6 S1579A mutant and Dab2 are quantitated and pre-
sented (Supplementary Figure S11). Collectively, the data
demonstrate that mutation of the phospho-Ser1579 site has
no effect on Wnt-mediated signalling, but that this site is
essential for LRP6/Dab2 interactions and for Dab2 to med-
iate its inhibitory activity on Wnt-mediated dorsoventral
patterning.
LRP6 S1579A mutant neutralizes Dab2 inhibition
of Wnt/b-catenin-mediated tumourigenesis
To determine whether LRP6/Dab2 interactions, and speciﬁ-
cally interactions through S1579, might be involved in the
putative tumour suppressor functions of Dab2, we performed
orthotopic allograft tumour studies in athymic nude mice.
Initially, we established stable cell lines in the mouse F9
background ectopically expressing Dab2, the DNG
LRP6 receptor, DNG LRP6 receptorþDab2, DNG S1579A
mutant LRP6 receptor and DNG S1579A mutant LRP6
receptorþDab2. Ectopic expression of the LRP6 receptor
constructs in the presence or absence of Dab2 is shown in
Figure 6A. Conﬁrming that expression of the intracellular
portion of the LRP6 receptor is sufﬁcient to mediate Wnt/
b-catenin signalling (Tamai et al, 2004), stable expression of
either DNG LRP6 or DNG S1579A mutant LRP6 receptor
results in increased TOPFlash activity (Figure 6B) and cyclin
D1 accumulation (Figure 6C). Stable co-expression of Dab2
with the DNG constructs demonstrates that Dab2 inhibits
DNG receptor-mediated signalling but not that of the DNG
S1579A mutant LRP6 receptor (Figures 6B and C).
Next, the various cell lines were injected into the left-side
ﬂanks of athymic nude mice and as a common control
F9-Dab2 cells were injected into the right-side ﬂanks, 10
mice for each cell line. At 45 days post inoculation, tumour
growth was monitored photographically (Figure 6D) or by
tumour weight (Figure 6E). The data show (left-side ﬂanks of
the mice in panel D) that parental F9 cells form small
tumours that reached a mean mass of B1g. Injection of F9-
Dab2 cells (right-side ﬂanks of the mice) failed to induce
tumour growth in either of the mice, indicating that Dab2
inhibits F9 tumour formation. F9 cells expressing either the
DNG or the mutant DNG S1579A LRP6 receptors induce
tumourigenesis, with tumours reaching a mean mass of
B3–4g. Growth of tumours induced by expression of the
DNG LRP6 receptor can be inhibited by co-expression of Dab2
(F9DNG-Dab2), whereas tumours induced by the mutant
DNG S1579A LRP6 receptor cannot be abrogated by co-
expression of Dab2 (Figures 6D and E). Cells isolated from
the primary tumours and expanded in culture (Figure 6F,
‘cultured cells’), as well as extracts prepared directly from
excised tumours (Figure 6F, ‘primary tumour’), maintain
stable ectopic expression of the LRP6 constructs (a-VSVG
blot) and of Dab2 (a-Dab2 blot). Further, haematoxylin and
eosin (H&E) staining (Figure 7A; H/E) and immunohisto-
chemical (IHC) staining of tumour sections revealed an
increased expression of cyclin D1 and b-catenin (Figure 7B
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These tumour studies conﬁrm the cellular analyses and
demonstrate that Wnt/LRP6-mediated tumourigenesis is in-
hibited by Dab2 expression and that this inhibition requires
LRP6/Dab2 interactions through the S1579 site of LRP6.
Knockdown of CK2 levels inhibits the tumour
suppressor functions of Dab2
To conﬁrm the role of CK2 in Dab2’s ability to modulate
LRP6-mediated tumourigenesis, we shRNA-silenced CK2
expression in F9-Dab2 cells and examined its effects on
Wnt/b-catenin signalling. Successful shRNA-mediated
silencing of CK2 was achieved (Figure 8A) and co-immu-
noprecipitation analysis (Figure 8A, middle panel) revealed
that Dab2 and LRP6 fail to interact in the CK2-attenuated
cells (F9-Dab2 CK2 KD) compared to the control shRNA
cells (F9-Dab2 cont.). We also compared Wnt/b-catenin
signalling in F9 and F9 CK2 knockdown cells, and no
signiﬁcant differences were observed (Supplementary
Figure S12). Further, compared with F9-Dab2 cells, in the
CK2 knockdown (F9-Dab2 CK2 KD) Dab2 fails to attenuate
transactivation of TOPFlash (Figure 8A, right panels).
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Figure 5 Dab2 fails to attenuate phospho-mutant S1579A LRP6-mediated dorsoventral patterning during zebraﬁsh embryonic development.
(A) Left panels: Control (MO) and zebraﬁsh LRP6 anti-sense (zLRP6) morpholinos (3ng) were injected into one-cell-stage fertilized zebraﬁsh
embryos and 24h post fertilization (hpf) photos were taken using a Leica MZ95 dissection microscope. Injection of zLRP6 MO yielded the
dorsoventralized phenotypes. Middle panels: Injection of zLRP6 MO (3ng) together with human LRP6 mRNA (hLRP6; 300pg) into one-cell-
stage zebraﬁsh embryos rescued the dorsoventralized phenotypes (MO zLRP6þWT hLRP6). Injection of zLRP6 MO (3ng) and hLRP6 mRNA
(300pg) and Dab2 mRNA (400pg) resulted in the dorsoventral phenotypes. Right panels: Co-injection of zLRP6 MO (3ng) with the hLRP6
phospho-mutant S1579A (hLRP6 1579A; 300pg) rescued the dorsoventralized phenotypes, and injection of these together with Dab2 (zLRP6
MOþhLRP6 1579AþDab2) failed to cause the dorsoventralized phenotypes. (B) Statistical analysis of the results from the injection assay of
panel A. (C) A set of injected embryos described in (A) were collected and proteins were extracted, followed by immunoblot and
immunoprecipitation analysis to detect expression levels of LRP6 and Dab2 using a-LRP6 and a-Flag antibodies. Figure source data can be
found with the Supplementary data.
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tumourigenesis (Figure 8B). Compared with F9-Dab2 cells
that fail to form tumours following inoculation (injected in
the left ﬂanks), F9-Dab2 cells in which CK2 has been
attenuated form tumours with a mean weight of B1g
(right ﬂanks). These data (Figures 8A and B) demonstrate
that CK2-mediated phosphorylation of LRP6 is required for
Dab2/LRP6 interactions and for Dab2’s ability to inhibit
Wnt3A-mediated signalling.
As depicted in our model (Figure 8C), the LRP6 receptor
has two endocytic fates following Wnt stimulation. In the
absence of Dab2, LRP6 is internalized in caveolin-containing
vesicles that presumably couple with and allow activation of
the b-catenin destruction complex. In cells that express Dab2,
Wnt3A-mediated activation of CK2 leads to LRP6 phosphor-
ylation at S1579, which promotes Dab2/LRP6 interactions
and shunting of the receptor to the clathrin endocytic path-
way. Wnt-mediated phosphorylation of LRP6 phosphoryla-
tion at S1490, postulated to be required for interaction with
and modulation of the b-catenin destruction complex, is not
observed when the receptor is internalized in clathrin-
containing vesicles. Thus, Dab2-mediated internalization of
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Figure 6 Dab2 fails to attenuate phospho-mutant S1579A LRP6-mediated tumourigenesis. (A) WCL from the indicated stably transfected cell
lines were analysed by immunoblot analysis using a-Dab2 and a-VSVG antibodies to detect the expression levels of Dab2 and the intracellular
domain of LRP6, respectively. (B) The relative TOP/FOPFlash luciferase activities and (C) expression levels of cyclin D1 in the stably
transfected cell lines stimulated with or without Wnt3A were determined. Data are presented as means±s.d. for three independent
experiments (n¼3), each experiment being performed in triplicate. Cyclin D1 expression levels were determined by immunoblot analysis
using a-cyclin D1 antibody. (D) Subcutaneous inoculation of 5 10
5 cells of the indicated stably transfected cell lines in the left hind ﬂank of
6-week-old BalbC athymic nude mice (nu/nu) was performed. Each animal was also inoculated with 5 10
5 cells of the F9-Dab2 cell line in the
right hind ﬂank serving as a control. Images were taken 45 days post injection. (E) Tumours were excised and tumour weight was evaluated as
a box-and-whisker plot to analyse differences between mean tumour weights among the various cells used. Data are presented as
means±s.e.m. for n¼10 samples per group. (F) Protein extracts from cultured cells established from the excised tumours (cultured cells)
or the primary tumours themselves (primary tumours) were analysed by immunoblot analysis using a-VSVG and a-Dab2 to detect relative
expression levels of Dab2 and VSVG-tagged DNG and DNG S1579A. Figure source data can be found with the Supplementary data.
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Discussion
We provide evidence that the tumour suppressor Dab2 med-
iates antagonistic effects on Wnt/b-catenin signalling through
its effects on LRP6 internalization. In the absence of Dab2,
Wnt induces the internalization of LRP6 through caveolin-
mediated endocytosis, resulting in Wnt/b-catenin signalling,
whereas in its presence Dab2 binds LRP6, in a Wnt and CK2-
dependent manner, and shunts LRP6 towards clathrin-
mediated endocytosis and suppression of b-catenin signalling
(Figure 8C). We postulate, therefore, that cellular Dab2 levels
modulate Wnt/b-catenin signalling by regulating the endocy-
tic fate of the LRP6 receptor.
Dab2 is an adaptor involved in endocytosis and protein
trafﬁcking (Bonifacino and Traub, 2003). Dab2 binds to
clathrin and the clathrin adaptor AP-2 and displays a
punctate ‘dot-like’ staining pattern in cells suggestive of its
association with intracellular vesicles (Morris and Cooper,
2001). On the basis of these data, and recent reports
demonstrating that internalization of Wnt receptor
complexes, through either caveolin or clathrin-mediated
routes, is critical for regulating Wnt signalling (Yamamoto
et al, 2008), we did observe an interaction between Dab2 and
LRP6. This interaction requires activation of Wnt signalling
or mere overexpression of the intracellular domain of LRP6.
Dab2 interaction with LRP6 does not involve the ﬁve
reiterated ‘PPPS/TP’ sites required for LRP6 to interact with
Axin (Tamai et al, 2004), but rather requires the highly
conserved Ser site at 1579. The data demonstrate that
phosphorylation of this site by CK2, in response to Wnt,
promotes binding of Dab2 and LRP6. Dab2/LRP6 interactions
do not affect the endocytic rate of LRP6, in that in the
presence or absence of Dab2 LRP6 receptors are
internalized with similar kinetics. Rather, Dab2’s binding to
LRP6 shunts the receptor away from its interaction with and
endocytosis by caveolin, and promotes its binding to and
endocytosis by clathrin. Mutation of S1579 does not abrogate
LRP6/Wnt-mediated signalling but prevents LRP6’s ability to
be phosphorylated by CK2, its interaction with Dab2 and its
shunting toward the clathrin endocytic pathway, and thus
inhibits Dab2’s antagonistic effect on Wnt/b-catenin
signalling. Signiﬁcantly, in our allograftic tumour studies
attenuation of Wnt signalling and tumour growth by Dab2
is observed only with the WT LRP6 DNG and not with the
phospho-S1579A LRP6 mutant DNG that fails to interact with
Dab2. Thus, S1579 of LRP6 represents a signiﬁcant negative
regulatory point of Wnt/b-catenin signalling and suggests
that mutation of this site may be targeted in tumourigenesis.
Our ﬁndings also corroborate previous studies by
Yamamoto et al, demonstrating that S1490 phosphorylation
is independent of LRP6 internalization but is essential for
b-catenin accumulation. Indeed, we did not observe Axin and
GSK3b in the LRP6 complex in the presence of Dab2, suggest-
ing that LRP6’s association with components of the b-catenin
complex, and ultimately b-catenin accumulation, occurs
downstream of LRP6 internalization in caveolin-containing
vesicles. In the presence of Dab2 and CK2 phosphorylation of
LRP6, the co-receptor is internalized through clathrin-
containing vesicles and fails to couple and modulate the
b-catenin destruction complex. Thus, although LRP6 is inter-
nalized, it fails to mediate accumulation of b-catenin in the
presence of Dab2.
DKK1, similarly to Dab2, inhibits Wnt3A-dependent stabi-
lization of b-catenin. However, while both DKK1 and Dab2
inhibit Wnt/b-catenin signalling by promoting LRP6 interna-
lization through the clathrin pathway, their inhibitory actions
differ in several important aspects: (1) whereas Dab2 inter-
acts with LRP6’s intracellular domain, DKK1 interacts with
the extracellular domain of LRP6; (2) mere expression of
DKK1 in cells induces internalization of LRP6 (Yamamoto
et al, 2008), whereas Dab2 expression has no effect on basal
or Wnt3A-induced LRP6 internalization. DKK1 does not
suppress Wnt3A-induced accumulation of b-catenin when
clathrin-mediated endocytosis is disrupted using MDC or in
clathrin knockdown cells (Yamamoto et al, 2008), suggesting
that DKK1-dependent internalization of LRP6 through
clathrin is required for its inhibitory effects on b-catenin
signalling. In contrast, Dab2’s inhibitory effects on
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Figure 7 IHC analysis of tumour tissues. (A) H&E staining of
excised tumours from mice inoculated with the indicated cell
lines. IHC analysis of parafﬁn sections from the excised tumours
was performed with a-cyclin D1 (B) and a–b-catenin (C). Scale bars,
50 mm.
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in that the MDC inhibitor does not attenuate Dab2’s
inhibitory effect; only clathrin knockdown inhibits Dab2’s
attenuation of Wnt signalling. Presumably, in the absence of
clathrin, Dab2 sequestration of LRP6 does not occur and the
receptor is free to internalize and signal through the caveolin
pathway upon Wnt3A stimulation. This indicates that Dab2’s
inhibitory effect requires interaction with clathrin and LRP6
resulting in sequestration of the receptor from the caveolin
pathway, and not LRP6 internalization.
There is now accumulating evidence that Wnt-induced
endocytosis is not only an obligatory step for b-catenin
signalling (Blitzer et al, 2006; Taelman et al, 2010) but is
also necessary for PCP signalling (Gagliardi et al, 2008;
Ohkawara et al, 2011). A ‘two endocytic routes–two out-
comes’ model for canonical Wnt/b-catenin signalling has
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Figure 8 Knockdown of CK2 inhibits the tumour suppressor functions of Dab2. (A) Left panels: F9-Dab2 stably expressing control shRNA or
CK2 shRNA were generated as described in Materials and methods and analysed by immunoblot analysis for expression levels of CK2, LRP6
and Dab2. Middle panels: Dab2 immunoprecipitates from F9-Dab2 stably expressing control shRNA or CK2 shRNA treated±Wnt3A were also
analysed for co-immunoprecipitation of LRP6. Right panel: Wnt3A-stimulated TOP/FOPFlash luciferase activity was determined in parental F9
cells, F9-Dab2-expressing cells with control shRNA and F9-Dab2-expressing cells in which CK2 is stably attenuated (F9-Dab2 CK2 KD).
(B) Subcutaneous inoculation of F9-Dab2 shCK2 cells (5 10
5) in the right hind ﬂank of 6-week-old BalbC athymic nude mice (nu/nu)w a s
performed. Each animal was also inoculated with 5 10
5 F9-Dab2 cells with control shRNA in the left hind ﬂank to serve as a control. Images
were taken 45 days post injection. Tumours were excised (middle panel) and tumour weight was evaluated as a box-and-whisker plot (right
panel) to analyse the differences between mean tumour weights. Data are presented as means±s.e.m. for n¼10 samples per group.
(C) Model depicting the shunting of LRP6 towards the clathrin endocytic pathway by Dab2. In the absence of Dab2, LRP6 is internalized
through the caveolin pathway, resulting in b-catenin accumulation, whereas in its presence LRP6 is internalized through the clathrin pathway
and fails to inhibit the b-catenin destruction complex. Figure source data can be found with the Supplementary data.
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through caveolin- or clathrin-dependent pathways resulting
in activation or inhibition of b-catenin, respectively
(Yamamoto et al, 2008). Our results conﬁrm this concept
and show that the endocytic adaptor Dab2 regulates the
sequestration of LRP6 towards clathrin-mediated
endocytosis. Thus, Dab2, presumably through its binding to
clathrin and the AP2 adaptor (Morris and Cooper, 2001), links
LRP6 to the endocytic machinery, while a similar adaptor
molecule linking LRP6 with the caveolin endocytic machinery
has yet to be identiﬁed. It appears, from our data, that
although LRP6 is internalized with similar kinetics in the
presence or absence of Dab2, once internalized the
endocytic fate of the receptor is distinct. In Dab2/clathrin-
containing endosomes, Wnt3A-mediated phosphorylation of
LRP6 at S1490 does not occur, suggesting that after being
internalized these Dab2 vesicles fail to engage the b-catenin
destruction complex and its associated CKI and GSK3b
kinases to phosphorylate LRP6. Presumably this endocytic
pathway is involved in receptor recycling, but whether it
mediates other Wnt signalling remains to be determined. On
the other hand, caveolin-containing endosomes, once
internalized, appear to couple with the b-catenin destruction
complex in that LRP6 phosphorylation at S1490 is observed.
Collectively, these data not only highlight the signiﬁcance of
LRP6 internalization in Wnt/b-catenin signalling but also
support the so-called ‘signalling endosome’ model whereby
endosomal vesicles serve as intracellular platforms for the
assembly of regulatory molecules and effectors that confer
signalling speciﬁcity and diversity. Perhaps the composition of
endocytic adaptor molecules such as Dab2 within these
endocytic platforms regulates signalosome formation and
thus signalling outcomes.
Materials and methods
Preparation of cell lysates, immunoblot analysis and
immunoprecipitation
For immunoprecipitation and immunoblot analysis, cells were lysed
in buffer D and immunoprecipitation was performed as described
previously (Jiang et al, 2008).
Biotin labelling of cell surface proteins and internalization
assays
For cell surface protein labelling, cells were treated in the presence
or absence of Wnt3A conditioned media at 371C for the times
indicated and washed three times with ice-cold phosphate-buffered
saline (PBS; pH 8.0) to remove any contaminating proteins. Cells
(2.5 10
7cells/ml) were resuspended in PBS and 50mlo f2 0 m M
Sulfo-NHS-SS-Biotin per millilitre of reaction volume was added.
Following a 1-h incubation on ice, cells were washed with Sulfo-
NHS-SS-Biotin blocking reagent (50mM NH4Cl in PBS containing
1mM MgCl2; 0.1mM CaCl2) to quench free Sulfo-NHS-SS-Biotin,
followed by several ice-cold PBS washes. Cell lysates were prepared
in buffer D followed by NeutrAvidin agrose beads (Pierce) precipi-
tation. Precipitates were washed three times with buffer D and
analysed by SDS–PAGE and immunoblotting with a-LRP6 and
a-EGFR antibodies. For internalization assays, cell surface proteins
were biotin-labelled as described above at room temperature for 1h,
followed by treatment with or without Wnt3A for the indicated
times at 371C. Following stimulation, cells were incubated with ice-
cold glutathione solution (60mM glutathione, 0.83M NaCl, with
0.83M NaOH and 1% bovine serum albumin (BSA) added before
use) for two 30-min incubations, followed by ice-cold PBS washes
four times. Cells were collected and lysed with buffer D and
biotinylated proteins precipitated with immobilized NeutrAvidin
agarose beads followed by SDS–PAGE and immunoblot analysis
with a-LRP6 and a-EGFR antibodies.
Immunoﬂuorescence and imaging
F9 and F9-Dab2 cells were treated with E1A control media or
Wnt3A conditioned media for 1h. Following treatment, cells were
ﬁxed for 20min in PBS buffer containing 4% (w/v) paraformalde-
hyde, followed by permeabilization with PBS containing 0.2%
(w/v) Triton X-100 and 2% BSA for 20min. Cells were incubated
with primary antibodies a-LRP6/a-caveolin or a-LRP6/a-clathrin
for 1h in permeabilization buffer followed by three washes with
PBS. Cells were incubated in secondary antibodies Alexa ﬂuor 488
(green) goat a-mouse and Alexa ﬂuor 568 (red) goat a-rabbit at
room temperature for 1h followed by three washes with PBS before
being observed with confocal laser scanning on a Leica TCS SP2
confocal microscope (Leica Microsystems, Germany).
In vivo tumourigenecity studies
Tumourigenesis was performed using subcutaneous injection of F9,
F9-Dab2, F9-DNG, F9-DNG-Dab2, F9-DNG S1579A or F9-DNG
S1579A-Dab2 cells (5 10
5) into the hind left ﬂank of 6-week-old
BalbC athymic nude mice (nu/nu), and F9-Dab2 cells were injected
into the hind right side as standard control. Ten animals were
used for each cell type. Post injection (45 days), all mice were
killed and images were taken. Tumours in mice were excised for
weight measurement and images taken. All experiments were
performed according to approved protocols of the Institutional
Animal Care and Use Committee (IACUC), Medical University of
South Carolina.
Immunohistochemistry
Immunohistochemistry was performed on parafﬁn-embedded sec-
tions as described (Hussey et al, 2011). Brieﬂy, tissue sections were
incubated with primary antibody a–b-catenin (Cell Signalling
Technology, 1:100) or a-cyclin D1 (Cell Signalling Technology,
1:100) for 2h at 251C. The sections were washed with PBS before
being incubated with the biotinylated secondary antibody for
30min at 251C. The stain was developed with diaminobenzidine
tetrahydrochloride (DAB) chromogen. Haematoxylin/eosin staining
was carried out with Ehrlich haematoxylin/eosin solution (Sigma-
Aldrich). All slides were observed and photos taken under a Leica
DM 2000 microscope.
Zebraﬁsh embryo microinjection
The WT AB zebraﬁsh strain was maintained and bred under
standard conditions and embryo microinjection was performed
following the standard protocol (Westerﬁeld, 2007). For more
detailed information, see Supplementary data.
Statistical analysis
All experiments were carried out at least three times. Data were
represented as mean±s.e.m. Signiﬁcance of differences between
two groups was tested by Student’s t test or ANOVA. A P value less
than 0.05 was regarded as signiﬁcant.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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